51 related articles for article (PubMed ID: 15082202)
1. Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group.
Niijima T
Cancer Immunol Immunother; 1989; 30(2):81-5. PubMed ID: 2598181
[TBL] [Abstract][Full Text] [Related]
2. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
4. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
Han RF; Pan JG
Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
[TBL] [Abstract][Full Text] [Related]
5. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy.
Blanc J; Ruggiero J; Lucca I; Arnold N; Kiss B; Roth B
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611077
[TBL] [Abstract][Full Text] [Related]
7. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
Zhang J; Li M; Chen Z; OuYang J; Ling Z
J Healthc Eng; 2021; 2021():2360717. PubMed ID: 34888022
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.
Tabayoyong WB; Kamat AM; O'Donnell MA; McKiernan JM; Ray-Zack MD; Palou J; Brausi M; Black PC; Williams SB
Eur Urol Focus; 2018 Jul; 4(4):512-521. PubMed ID: 30190111
[TBL] [Abstract][Full Text] [Related]
10. Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.
Liu Q; Zhang C; Ding X; Deng H; Zhang D; Cui W; Xu H; Wang Y; Xu W; Lv L; Zhang H; He Y; Wu Q; Szyf M; Ho CM; Zhu J
Sci Rep; 2015 Jun; 5():11464. PubMed ID: 26088171
[TBL] [Abstract][Full Text] [Related]
11. Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis of the published results of randomized clinical trials.
Li T; Xing Y; Liu SC; Han XM; Li WC; Chen M
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):706-715. PubMed ID: 25318881
[TBL] [Abstract][Full Text] [Related]
12. Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?
Hong S; Kim SC; Kwon T; Jeong IG; Kim CS; Ahn H; Hong JH
PLoS One; 2014; 9(7):e103791. PubMed ID: 25072158
[TBL] [Abstract][Full Text] [Related]
13. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
Ersoy H; Yaytokgil M; Karakoyunlu AN; Topaloglu H; Sagnak L; Ozok HU
Drug Des Devel Ther; 2013; 7():1-6. PubMed ID: 23300343
[TBL] [Abstract][Full Text] [Related]
14. The management of non-invasive bladder tumours with Doxorubicin intravesical instillation after transurethral resection.
Al-Gallab MI; Naddaf LA; Kanan MR
Sultan Qaboos Univ Med J; 2009 Apr; 9(1):53-8. PubMed ID: 21509275
[TBL] [Abstract][Full Text] [Related]
15. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
16. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.
Sylvester RJ; Oosterlinck W; Witjes JA
Eur Urol; 2008 Apr; 53(4):709-19. PubMed ID: 18207317
[TBL] [Abstract][Full Text] [Related]
17. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Liu B; Wang Z; Chen B; Yu J; Zhang P; Ding Q; Zhang Y
Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
